Rathbones Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Rathbones Group’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.9K	Hold	35,000	–	–	﹤0.01%	657
2026 Q1	$55.3K	Hold	35,000	–	–	﹤0.01%	633
2025 Q4	$58.5K	Hold	35,000	–	–	﹤0.01%	619
2025 Q3	$59.1K	Hold	35,000	–	–	﹤0.01%	622
2025 Q2	$31.8K	Hold	35,000	–	–	﹤0.01%	616
2025 Q1	$15.8K	Hold	35,000	–	–	﹤0.01%	596
2024 Q4	$17.6K	Hold	35,000	–	–	﹤0.01%	602
2024 Q3	$31.7K	Hold	35,000	–	–	﹤0.01%	594
2024 Q2	$34.9K	Hold	35,000	–	–	﹤0.01%	600
2024 Q1	$51.8K	Hold	35,000	–	–	﹤0.01%	591
2023 Q4	$38.1K	Hold	35,000	–	–	﹤0.01%	590
2023 Q3	$41.3K	Buy	+35,000	New	+$47.6K	﹤0.01%	597

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rathbones Group's LCTX Position: Q2 2026 in Review

Rathbones Group held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 35,000 shares worth $45.9K. The position accounts for ﹤0.01% of the portfolio, ranked #657.

Rathbones Group first reported a position in LCTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $59.1K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Rathbones Group held 35,000 shares of Lineage Cell Therapeutics worth $45.9K as of Q2 2026.
Rathbones Group left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Rathbones Group's portfolio in Q2 2026, its #657 holding.
Rathbones Group first reported a position in Lineage Cell Therapeutics in Q3 2023 and has held it in 12 quarters since.
Rathbones Group's Lineage Cell Therapeutics position peaked at $59.1K in Q3 2025.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.